Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced Warren Sherman, MD, Chief Medical Officer, has been invited to Chair the U.S. National Heart, Lung and Blood Institute Special Emphasis Panel on Production Assistance for Cellular Therapies (PACT). The panel meeting will be held on Tuesday, September 29, 2015 in Washington, D.C.
Dr. Sherman will be responsible for managing the PACT panel, which will put an emphasis on assistance with cellular therapy translational research and the manufacture of cellular therapy products for investigational new drug (IND) enabling pre-clinical studies.
Dr. Sherman has served as the CMO of Celyad since October 2014. He is an American interventional cardiologist with more than 30 years of experience in the field, and a focus on cell-based therapies for treating patients post myocardial infarction and with heart failure. Dr. Sherman is certified by the American Board of Internal Medicine in Cardiology and Interventional Cardiology, and he serves as an advisor to a multitude of government organizations, societies and industries.
"It is an honor to have been selected as Chair of this prestigious meeting," commented Dr. Sherman. "The National Heart, Lung, and Blood Institute is an organization that stimulates discoveries surrounding these diseases, making advances to benefit the public. I am excited to be a part of their progress."
Celyad CEO Christian Homsy added, "We are proud to have our own Dr. Sherman chair this important meeting. The invitation recognizes his extensive experience and leadership in cell therapies in cardiology. These are the same reasons that we are glad to have him as a part of the Celyad team."